For decades, European regulatory agencies required pharmaceutical manufacturers to submit extensive post-market safety monitoring reports every five years. Recently, industry trade groups argued that this reporting requirement imposes severe financial burdens on small biotech firms. However, public health advocates note that post-market safety reports have led to the early detection of severe adverse drug interactions in over forty instances since their implementation. Therefore, despite the financial objections raised by trade groups, the regulatory agencies should maintain the mandatory five-year reporting schedule.
In the argument above, the claim that European regulatory agencies have required pharmaceutical manufacturers to submit post-market safety monitoring reports every five years plays which of the following roles?
- It provides background information establishing the regulatory context within which the overall debate takes place.Answer
- BIt is a premise offered directly by the author to support the recommendation that the reporting schedule be maintained.
- CIt is an intermediate conclusion drawn from the evidence presented regarding adverse drug interactions.
- DIt presents a counterargument that the author attempts to refute in order to justify maintaining the requirement.
- EIt states the primary conclusion toward which the argument as a whole is directed.